



Marinus Pharmaceuticals  
Investor Relations Department  
170 N. Radnor Chester Road,  
Suite 250  
Radnor, PA 19087-5279  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### NASDAQ: MRNS

|               |   |
|---------------|---|
| Last Trade:   | 7.89  |
| Trade Time:   | 4:00 PM ET<br>Dec 15, 2017                          |
| Change:       | -1.44 <span style="color: red;">↓</span> (-15.434%) |
| Day Range     | 7.77 - 9.45   |
| 52-Week Range | 0.83 - 9.87   |
| Volume        | 3,606,517   |


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Marinus is committed to maximizing shareholder value by developing and commercializing ganaxolone for treatment of drug-resistant seizures in both the hospital and home settings.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Dec 13, 2017*

[Marinus Pharmaceuticals Added to NASDAQ Biotechnology Index](#)

*Oct 31, 2017*

[Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2017 Financial Results](#)

*Sep 21, 2017*

[Marinus Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference](#)

*Sep 19, 2017*

[Marinus Pharmaceuticals Announces closing of Public Offering of Common Stock and full exercise of underwriter's option to purchase additional shares](#)

*Sep 15, 2017*

[Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock](#)

## Financials & Filings [\[ View all \]](#)

[Third Quarter Financial Results](#)

*Mar 13, 2017*

[Annual Report \(10-K\)](#)

*Mar 16, 2017*

[Proxy Statement \(DEF 14A\)](#)

*Oct 31, 2017*

[Quarterly Report \(10-Q\)](#)

*Aug 1, 2017*

[Quarterly Report \(10-Q\)](#)

*May 1, 2017*

[Quarterly Report \(10-Q\)](#)